Select Publications
Conference Abstracts
2024, 'Does use of smoking cessation pharmacotherapies during pregnancy increase the risk of congenital malformations in infants: Findings from a multi-national study', Edinburgh, Scotland, United Kingdom, presented at Society for Research on Nicotine and Tobacco Annual Meeting, Edinburgh, Scotland, United Kingdom, 20 March 2024 - 23 March 2024
,2023, 'Prevalence of smoking cessation pharmacotherapy use during pregnancy: a multi-national population-based study', Sydney, presented at Centre of Research Excellence in Medicines Intelligence Symposium 2023, Sydney, 02 November 2023 - 03 November 2023
,2023, 'The risk of congenital malformations in infants exposed in the first trimester to smoking cessation pharmacotherapies: A multi-national cohort study', Sydney, presented at Centre of Research Excellence in Medicines Intelligence Symposium 2023, Sydney, 02 November 2023 - 03 November 2023
,2023, 'Utilisation of smoking cessation pharmacotherapies during pregnancy: a multi-national population-based study', Adelaide, South Australia, presented at APSAD Australasian Professional Society on Alcohol and other Drugs 2023, Adelaide, South Australia, 27 October 2023 - 30 October 2023
,2023, 'The safety of quit smoking medications during pregnancy: the risk of congenital malformations in infants', UNSW Sydney, presented at National Drug and Alcohol Research Centre Symposium 2023, UNSW Sydney, 26 October 2023
,2023, 'First trimester exposure to smoking cessation pharmacotherapies and the risk of major congenital malformations: A multi-national cohort study', Halifax, Nova Scotia, Canada, presented at 39th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Halifax, Nova Scotia, Canada, 23 August 2023
,2023, 'Trends in the use of Cardiometabolic Medicines in Australia (2014-2022): Sodium-glucose Co-transporter 2 Inhibitors and Glucagon-like Peptide-1 Analogues', in Trends in the use of Cardiometabolic Medicines in Australia (2014-2022): Sodium-glucose Co-transporter 2 Inhibitors and Glucagon-like Peptide-1 Analogues, presented at Australian Diabetes Congress 2023
,2023, 'Trends in use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 analogues (GLP-1a) for cardiovascular risk in Australia (2014-2022)', in Trends in use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 analogues (GLP-1a) for cardiovascular risk in Australia (2014-2022), presented at 39th International Conference on Pharmacoepidemiology & Therapeutic Risk Management 2023
,2022, 'Patterns of ADHD medicine use: A population-based study among Australian children and adults (2013-2020)', in PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, WILEY, Vol. 31, pp. 71 - 71, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000859084400136&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2022, 'Disparities in the prehospital management of stroke between women and men in New South Wales', in INTERNATIONAL JOURNAL OF STROKE, SAGE PUBLICATIONS LTD, Vol. 17, pp. 18 - 18, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000847720500050&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2022, 'ANZARD Data Linkage – Agreement Between Births Recorded by Clinics and in NSW Perinatal Data Collection', in Fertility & Reproduction, World Scientific Pub Co Pte Ltd, Vol. 04, pp. 176 - 176, http://dx.doi.org/10.1142/s2661318222740875
,2021, 'Children's relative age and medicine treatment for attention-deficit/hyperactivity disorder (ADHD) across Australian jurisdictions with different school enrolment policies', in PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, WILEY, Vol. 30, pp. 166 - 167, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000687807300335&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2021, 'Medical morbidity and mortality in Australians with bipolar disorder from linked administrative data', in BIPOLAR DISORDERS, WILEY, Vol. 23, pp. 51 - 52, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000663051300119&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2020, 'Maternal and Neonatal Outcomes Associated with Psychostimulant Use in Pregnancy', in International Journal of Population Data Science, Swansea University, Vol. 5, http://dx.doi.org/10.23889/ijpds.v5i5.1579
,2019, 'Identification and characterisation of bipolar disorder in Australia using administrative health data', in BIPOLAR DISORDERS, WILEY, AUSTRALIA, Sydney, Vol. 21, pp. 69 - 70, presented at 21st Annual ISBD Conference on Global Advances in Bipolar Disorder and Depression, AUSTRALIA, Sydney, 20 March 2019 - 23 March 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000461513600148&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2018, 'Antipsychotic drug use in pregnancy: A multinational database study', in PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, WILEY, Vol. 27, pp. 235 - 235
,2009, 'MAILED FEEDBACK FOR AT-RISK DRINKERS PRESENTING TO RURAL EMERGENCY DEPARTMENTS', in DRUG AND ALCOHOL REVIEW, WILEY-BLACKWELL PUBLISHING, INC, Vol. 28, pp. A28 - A28, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000270916300088&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,